

**Provisional Draft Agenda**  
**49th meeting of the Committee for Socio-economic Analysis**

**30 November-4 December 2020**  
**and**  
**8-10 December 2020**

**Web-based meeting**

**Monday 30 November starts at 14.00**  
**Friday 4 December breaks at 13.30**  
**Tuesday 8 December resumes at 10.00**  
**Thursday 10 December ends at 13.30**

***Times are Helsinki times***

**Item 1 – Welcome and Apologies**

**Item 2 – Adoption of the Agenda**

***SEAC/A/49/2020***  
***For adoption***

**Item 3 – Declarations of conflicts of interest to the Agenda**

**Item 4 – Report from other ECHA bodies and activities**

- a) Report on SEAC-48 action points, written procedures and update on other ECHA bodies

***For information***

**Item 5 – Restrictions**

**5.1 General restriction issues**

- a) Essential uses  
b) Updated Framework for RAC and SEAC in checking conformity and developing opinions on restriction proposals

## 5.2 Restriction Annex XV dossiers

a) Conformity check and key issues discussion

1) Substances in single-use nappies

***For discussion and agreement***

b) Opinion development

1) Undecafluorohexanoic acid (PFHxA), its salts and related substances – third draft opinion

***For discussion***

2) Microplastics – draft final opinion

***For discussion and adoption***

## 5.2 Appointment of (co-)rapporteurs for restriction dossiers

***Doc to be distributed***

***For agreement***

## Item 6 – Authorisation

### 6.1 General authorisation issues

a) Update on incoming/future applications  
b) Horizontal AfA issues

***For information***

### 6.2 Authorisation applications

a) Discussion on key issues

1) 9 applications for authorisation (EDC, Cr(VI), MOCA, 4-tert-OPnEO) from August 2020 submission window

***For discussion***

b) Agreement on draft opinion

- 1) 196\_OPE\_Becton (1 use)
- 2) 197\_OPE\_NPE\_Phadia (2 uses)
- 3) 199\_OPE\_Biokit (2 uses)
- 4) 202\_OPE\_Merckle (1 use)
- 5) 203\_OPE\_NPE\_Qiagen (4 uses)
- 6) 208\_RR1\_TCE\_BlueCube (1 use)

- 7) 209\_CT\_Safran (1 use)
- 8) 210\_CT\_Hubner (3 uses)
- 9) 211\_CT\_SD\_TataSteel (1 use)

***For discussion and agreement***

c) Adoption of opinion

- 1) 143\_OPE\_bioMerieux (3 uses)
- 2) 147\_CTPht\_Bilbaina (1 use)
- 3) 148\_CTPht\_DEZA (1 use)
- 4) 149\_CTPht\_Nalon (1 use)
- 5) 150\_CTPht\_AO\_Koppers (1 use)
- 6) 153\_CTPht\_AO\_Bilbaina (1 use)
- 7) 162\_OPE\_LFB (1 use)
- 8) 176\_OPE\_Abbott\_1 (5 uses)
- 9) 184\_OPE\_Lilly (1 use)
- 10) 186\_OPE\_NPE\_Beckman (5 uses)
- 11) 187\_OPE\_AGC (2 uses)
- 12) 188\_OPE\_Wallac\_2 (2 uses)

***For discussion and adoption***

### **6.3 Appointment of (co-)rapporteurs for authorisation applications**

***Doc to be distributed***

***For agreement***

#### **Item 7 – Article 77(3)(c) requests**

- 1) Perfluorooctanoic acid (PFOA), its salts and PFOA-related substances

***For discussion and adoption***

- 2) Substitution Plans

**For discussion**

#### **Item 8 – AOB**

- a) Update of the work plan

***For information***

#### **Item 9 – Action points and main conclusions of SEAC-49**

Table with Conclusions and Action points from SEAC-49

***For adoption***